Biogen’s drug approval in Alzheimer’s spurs three FDA advisers to resign

Three members of the U.S. Food and Drug Administration’s advisory panel on diseases of the central nervous system have now resigned over the controversial approval of Aduhelm, Biogen Inc.’s new Alzheimer’s disease drug.